Results from the ARCHES trial presented yesterday in San Francisco

On Thursday, here in San Francisco, Dr. Andrew Armstrong first presented the results of the so-called ARCHES trial of enzalutamide (Xtandi) + standard androgen deprivation therapy (ADT) in the treatment of men with metastatic, “hormone-sensitive” prostate cancer (mHSPC). … READ MORE …

Pfizer completes acquisition of Medivation

As of midnight last night, Pfizer completed the acquisition of Medivation and therefore enzalutamide (Xtandi) is now being sold in the USA by Pfizer and Astellas and by Astellas in the rest of the world. For the details, see here.

Pfizer to buy Medivation (developer of Xtandi)

According to news this morning, Pfizer has entered into a merger agreement which will allow the company to buy Medivation (the developer of enzalutamide, also known as Xtandi). Rumors had been rife since last Friday. … READ MORE …

The price — and the politics — of drug therapy for advanced prostate cancer

According to a story on the MarketWatch web site yesterday, two not-for-profit organizations have been seeking hearings on revocation of patents held by Medivation on the drug enzalutamide (Xtandi). … READ MORE …

Xtandi beats out Zytiga in NICE evaluation in the UK

According to an article this morning on the PharmaTimes web site,  Astellas has convinced the National Institute for Health and Care Excellence (NICE) to recommend coverage of enzalutamide (Xandi) in chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Overall survival and rPFS data from the PREVAIL trial expected later this year

According to a media release issued by Astellas Pharma and Medivation, the companies now expect to conduct an interim analysis of the PREVAIL trial of enzalutamide (a.k.a. MDV3100 or Xtandi) for overall survival some time later this year. … READ MORE …